Dapagliflozin

CAS : 461432-26-8

Ref. 3D-MD20795

Informations sur le produit

• Nom: Dapagliflozin
• Synonymes: (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitolBMS 512148, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-<span class="text-smallcaps">D</span>-glucitol, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol, <span class="text-smallcaps">D</span>-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, Bms-512148, D-Glucitol, 1,5-Anhydro-1-C-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-, (1S)-, Dapagliflozin free base, (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Description

Dapagliflozin is a sodium-glucose cotransporter subtype 2 (SGLT2) inhibitor that can be used in the treatment of diabetes mellitus type 2. SGLT2 is located in the proximal convoluted tubule and when it is inhibited the reabsorption of glucose into the kidneys is prevented and instead glucose is excreted in the urine. As a result glucose levels are reduced. Dapagliflozin is metabolized into to its inactive metabolite 3-O-glucuronide by the UGT1A9 enzyme present in the liver and the kidneys. In addition, dapagliflozin has been shown to cause weight loss and decrease the risk of cardiovascular events such as congestive heart failure.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 408.87 g/mol
• Formule: C₂₁H₂₅ClO₆
• Degré de pureté: Min. 98 Area-%
• Couleur/Forme: White Yellow Powder